← 홈

Antibody · 방광·요로상피

30개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 30개
AntibodystaleWeill Medical College of Cornel…Phase 1

Naptumomab Estafenatox (Naptumomab Estafenatox)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSwiss Cancer InstitutePhase 2

durvalumab (Imfinzi, Neoadjuvant and adjuvant durvalumab)

Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSeoul National University Hospi…Preclinical

atezolizumab (Tecentriq, Neoadjuvant atezolizumab)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel)

Metastatic Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Rezetecan Combined with Adebelizumab)

Muscle-Invasive Bladder Cancer (MIBC) · Muscle-Invasive Bladder Cancer (MIBC)

#Muscle-InvasiveBladderCancerMIBC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE
AntibodystaleMedPacto, Inc.Phase 2

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent

#UrothelialCarcinomaRecurrent#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#항체#면역항체+3
효능 ORR 7%임상시험 1상태 RECRUITING

2 / 2 페이지

← 이전다음 →